期刊
POLYMER TESTING
卷 110, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.polymertesting.2022.107584
关键词
Osteoporosis; Nanoparticles; Bone-targeted; Alendronate
资金
- Basic scientific research operating expenses of provincial universities [SJLY2021002]
- Science and Technology Innovation Commission of Shenzhen [ZDSYS20200811142600003, JCYJ20180507183036060, JCYJ20190806161409092, JCYJ20210324103012033]
- Natural Science Foundation of Guangdong Province [2021A1515010720, 2019A1515011750]
- K. C. Wong Magna Fund in Ningbo University
- Key Laboratory of Advanced Mass Spectrometry and Molecular Analysis of Zhejiang Province
- European Commission via H2020-MSCA-RISE Program [734156]
- Versus Arthritis [21160, 21977]
Bone-targeted polymeric nanoparticles for alendronate delivery were fabricated and shown to have sustained release and good cytocompatibility, with high affinity to bone cells.
Bone-targeted polymeric nanoparticles for alendronate delivery based on Poly (lactic-co-glycolic acid) conju-gated chitosan (CS-PLGA) and alendronate conjugated PLGA (Alen-PLGA) are fabricated and their superior performances are evaluated. The nanoparticles exhibited sustained Alen release without obvious burst release and good cytocompatibility against MC3T3 cells. Alen-modified nanoparticles demonstrated a high affinity to hydroxyapatite, which is the main mineral component of bone, indicating their feasibility for bone-targeted delivery. In addition, unlike nanoparticles without Alen, Alen-modified nanoparticles were preferentially taken up by MC3T3 cells, compared to HDF cells, revealing their specific uptake for osteoblast-like cells. Thus, the Alen-modified nanoparticles can potentially be developed as bone-targeted carriers for osteoporosis treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
